Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 4Melanoma 4Pancreatic Neoplasms 3Neurofibroma, Plexiform 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thymoma 1Small Cell Lung Carcinoma 1Sarcoma 1Peripheral Nervous System Diseases 1Pain 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Heredodegenerative Disorders, Nervous System 1

Interventions

AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Peripheral Nervous System Diseases × AZD 6244 × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡